Düşük Over Rezervli Hastaların İnfertilite Yönetimi

Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency(). Hum Reprod Open. 2024;2024(4):hoae065.

Ovarian Stimulation T, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI(dagger). Hum Reprod Open. 2020;2020(2):hoaa009.

Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. 2011;96(12):3864-3872.

Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-1624.

Lee HJ, Noh HK, Joo JK. Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria. Sci Rep. 2022;12(1):17723.

Datta AK, Campbell S, Felix N, et al. Oocyte or embryo number needed to optimize live birth and cumulative live birth rates in mild stimulation IVF cycles. Reprod Biomed Online. 2021;43(2):223-232.

Khalife D, Nassar A, Khalil A, et al. Cumulative Live-Birth Rates by Maternal Age after One or Multiple In Vitro Fertilization Cycles: An Institutional Experience. Int J Fertil Steril. 2020;14(1):34-40.

Cakmak H. When is the right time to stop autologous in vitro fertilization treatment in poor responders? Fertil Steril. 2022;117(4):682-687.

Poseidon G, Alviggi C, Andersen CY, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452-1453.

Roque M, Haahr T, Esteves SC, et al. The POSEIDON stratification - moving from poor ovarian response to low prognosis. JBRA Assist Reprod. 2021;25(2):282-292.

Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26(7):1768-1774.

Richardson MC, Guo M, Fauser BC, et al. Environmental and developmental origins of ovarian reserve. Hum Reprod Update. 2014;20(3):353-369.

Sharara FI, Beatse SN, Leonardi MR, et al. Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test. Fertil Steril. 1994;62(2):257-262.

Zenzes MT, Reed TE, Casper RF. Effects of cigarette smoking and age on the maturation of human oocytes. Hum Reprod. 1997;12(8):1736-1741.

Rosevear SK, Holt DW, Lee TD, et al. Smoking and decreased fertilisation rates in vitro. Lancet. 1992;340(8829):1195-1196.

Ge W, Li L, Dyce PW, et al. Establishment and depletion of the ovarian reserve: physiology and impact of environmental chemicals. Cell Mol Life Sci. 2019;76(9):1729-1746.

Burger HG. Androgen production in women. Fertil Steril. 2002;77 Suppl 4:S3-5.

Conforti A, Carbone L, Di Girolamo R, et al. Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2025;123(3):457-476.

Norman RJ, Alvino H, Hull LM, et al. Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reprod Biomed Online. 2019;38(6):908-915.

Choe SA, Kim MJ, Lee HJ, et al. Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled study. Arch Gynecol Obstet. 2018;297(3):791-796.

Lee YX, Shen MS, Tzeng CR. Low Dose Growth Hormone Adjuvant Treatment With Ultra-Long Ovarian Stimulation Protocol in Poor Responders Showed Non-inferior Pregnancy Outcome Compared With Normal Responders. Front Endocrinol (Lausanne). 2019;10:892.

Xu Y, Nisenblat V, Lu C, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reprod Biol Endocrinol. 2018;16(1):29.

Shang Y, Song N, He R, et al. Antioxidants and Fertility in Women with Ovarian Aging: A Systematic Review and Meta-Analysis. Adv Nutr. 2024;15(8):100273.

Artini PG, Tatone C, Sperduti S, et al. Cumulus cells surrounding oocytes with high developmental competence exhibit down-regulation of phosphoinositol 1,3 kinase/protein kinase B (PI3K/AKT) signalling genes involved in proliferation and survival. Hum Reprod. 2017;32(12):2474-2484.

Placidi M, Casoli G, Tatone C, et al. Myo-Inositol and Its Derivatives: Their Roles in the Challenges of Infertility. Biology (Basel). 2024;13(11).

Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162-1172.

Pantos K, Nitsos N, Kokkali G, et al. Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after autologous platelet-rich plasma treatment. Hum Reprod. 2016;31(Suppl 1):i301.

Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. J Clin Med. 2020;9(6).

Barrenetxea G, Celis R, Barrenetxea J, et al. Intraovarian platelet-rich plasma injection and IVF outcomes in patients with poor ovarian response: a double-blind randomized controlled trial. Hum Reprod. 2024;39(4):760-769.

Herraiz S, Romeu M, Buigues A, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril. 2018;110(3):496-505 e491.

Romanski PA, Bortoletto P, Rosenwaks Z, et al. Delay in IVF treatment up to 180 days does not affect pregnancy outcomes in women with diminished ovarian reserve. Hum Reprod. 2020;35(7):1630-1636.

Harris BS, Jukic AM, Truong T, et al. Markers of ovarian reserve as predictors of future fertility. Fertil Steril. 2023;119(1):99-106.

Polyzos NP, Popovic-Todorovic B. SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same. Hum Reprod. 2020;35(9):1964-1971.

Esteves SC, Carvalho JF, Martinhago CD, et al. Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model. Panminerva Med. 2019;61(1):3-10.

Polyzos NP, Blockeel C, Verpoest W, et al. Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria. Hum Reprod. 2012;27(12):3481-3486.

Kedem A, Tsur A, Haas J, et al. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation? Fertil Steril. 2014;101(6):1624-1628.

Garcia-Velasco JA, Bermejo A, Ruiz F, et al. Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertil Steril. 2011;96(3):590-593.

Hauzman EE, Zapata A, Bermejo A, et al. Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial. Reprod Biol Endocrinol. 2013;11:96.

Tsampras N, Gould D, Fitzgerald CT. Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients. Hum Fertil (Camb). 2017;20(4):248-253.

Cerrillo M, Cecchino GN, Toribio M, et al. A randomized, non-inferiority trial on the DuoStim strategy in PGT-A cycles. Reprod Biomed Online. 2023;46(3):536-542.

Vaiarelli A, Cimadomo D, Trabucco E, et al. Double Stimulation in the Same Ovarian Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved From Poor Prognosis Patients: A Multicenter Experience and SWOT Analysis. Front Endocrinol (Lausanne). 2018;9:317.

Ashrafi M, Arabipoor A, Yahyaei A, et al. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial. Reprod Biol Endocrinol. 2018;16(1):124.

Davar R, Neghab N, Naghshineh E. Pregnancy outcome in delayed start antagonist versus microdose flare GnRH agonist protocol in poor responders undergoing IVF/ICSI: An RCT. Int J Reprod Biomed. 2018;16(4):255-260.

Esfidani T, Moini A, Arabipoor A, et al. Early administration of gonadotropin-releasing hormone antagonist versus flexible antagonist ovarian stimulation protocol in poor responders: a randomized clinical trial. Middle East Fertility Society Journal. 2021;26(1):35.

Benadiva CA, Davis O, Kligman I, et al. Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients. J Assist Reprod Genet. 1995;12(1):8-12.

Casarini L, Santi D, Brigante G, et al. Two Hormones for One Receptor: Evolution, Biochemistry, Actions, and Pathophysiology of LH and hCG. Endocr Rev. 2018;39(5):549-592.

Devroey P, Pellicer A, Nyboe Andersen A, et al. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97(3):561-571.

Fauser BC, Alper MM, Ledger W, et al. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2011;22 Suppl 1:S23-31.

Drakopoulos P, Vuong TNL, Ho NAV, et al. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Hum Reprod. 2017;32(11):2225-2233.

Fusi FM, Zanga L, Arnoldi M, et al. Corifollitropin alfa for poor responders patients, a prospective randomized study. Reprod Biol Endocrinol. 2020;18(1):67.

Berkkanoglu M, Ozgur K. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil Steril. 2010;94(2):662-665.

Weil S, Vendola K, Zhou J, et al. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab. 1999;84(8):2951-2956.

Humaidan P, Chin W, Rogoff D, et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017;32(7):1537-1538.

Tosun SA, Ozkaya E, Aru B, et al. Does LH supplementation in poor responders affect granulosa cells apoptosis rate in ART? A prospective randomised controlled trial. J Obstet Gynaecol. 2022;42(1):133-138.

Dosouto C, Haahr T, Humaidan P. Advances in ovulation trigger strategies. Panminerva Med. 2019;61(1):42-51.

Keskin M, Ecemis T, Atik A, et al. Cycle outcomes of dual trigger (GnRH agonist+hCG) versus human chorionic gonadotropin trigger alone in POSEDION group 3-4 poor-responders and normo-responders: A prospective randomized study. J Gynecol Obstet Hum Reprod. 2023;52(8):102633.

Zagadailov P, Hsu A, Seifer DB, et al. Differences in utilization of Intracytoplasmic sperm injection (ICSI) within human services (HHS) regions and metropolitan megaregions in the U.S. Reprod Biol Endocrinol. 2017;15(1):45.

Check JH, Chase DS, Horwath D, et al. Oocytes from women of advanced reproductive age do not appear to have an increased risk of zona pellucida hardening. Clin Exp Obstet Gynecol. 2012;39(4):440-441.

Zhu S, Jiang W, Liao X, et al. Effect of diminished ovarian reserve on the outcome of fresh embryo transfer in IVF/ICSI cycles among young women: A retrospective cohort study. BMC Womens Health. 2024;24(1):230.

Hu YL, Wang Y, Geng LH, et al. Effects of sequential cleavage and blastocyst embryo transfer on pregnancy outcomes in patients with poor ovarian response. J Reprod Immunol. 2023;155:103780.

Wang SF, Seifer DB. Age-related increase in live-birth rates of first frozen thaw embryo versus first fresh transfer in initial assisted reproductive technology cycles without PGT. Reprod Biol Endocrinol. 2024;22(1):42.

Carnesi E, Castellano S, Albani E, et al. Diminished ovarian reserve is associated to euploidy rate: a single center study. Front Endocrinol (Lausanne). 2024;15:1535776.

Jaswa EG, McCulloch CE, Simbulan R, et al. Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. Fertil Steril. 2021;115(4):966-973.

Morin SJ, Patounakis G, Juneau CR, et al. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance. Hum Reprod. 2018;33(8):1489-1498.

Stovezky YR, Romanski PA, Bortoletto P, et al. Antimullerian hormone is not associated with embryo ploidy in patients with and without infertility undergoing in vitro fertilization with preimplantation genetic testing. Fertil Steril. 2023;119(3):444-453.

Transfer EGGotNoEt, Alteri A, Arroyo G, et al. ESHRE guideline: number of embryos to transfer during IVF/ICSIdagger. Hum Reprod. 2024;39(4):647-657.

Practice Committee of the American Society for Reproductive M, the Practice Committee for the Society for Assisted Reproductive Technologies. Electronic address Aao. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril. 2021;116(3):651-654.

Wang MJ, Lin MH, Yang JH, et al. Low antimullerian hormone (<1.2 ng/ml) does not impact oocyte quality and IVF/ICSI outcomes in women =40 years old. Taiwan J Obstet Gynecol. 2025;64(2):248-252.

Li NJ, Yao QY, Yuan XQ, et al. Anti-mullerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis. Arch Gynecol Obstet. 2023;308(1):43-61.

Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency(). Hum Reprod Open. 2024;2024(4):hoae065.

Ovarian Stimulation T, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI(dagger). Hum Reprod Open. 2020;2020(2):hoaa009.

Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. 2011;96(12):3864-3872.

Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-1624.

Lee HJ, Noh HK, Joo JK. Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria. Sci Rep. 2022;12(1):17723.

Datta AK, Campbell S, Felix N, et al. Oocyte or embryo number needed to optimize live birth and cumulative live birth rates in mild stimulation IVF cycles. Reprod Biomed Online. 2021;43(2):223-232.

Khalife D, Nassar A, Khalil A, et al. Cumulative Live-Birth Rates by Maternal Age after One or Multiple In Vitro Fertilization Cycles: An Institutional Experience. Int J Fertil Steril. 2020;14(1):34-40.

Cakmak H. When is the right time to stop autologous in vitro fertilization treatment in poor responders? Fertil Steril. 2022;117(4):682-687.

Poseidon G, Alviggi C, Andersen CY, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452-1453.

Roque M, Haahr T, Esteves SC, et al. The POSEIDON stratification - moving from poor ovarian response to low prognosis. JBRA Assist Reprod. 2021;25(2):282-292.

Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26(7):1768-1774.

Richardson MC, Guo M, Fauser BC, et al. Environmental and developmental origins of ovarian reserve. Hum Reprod Update. 2014;20(3):353-369.

Sharara FI, Beatse SN, Leonardi MR, et al. Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test. Fertil Steril. 1994;62(2):257-262.

Zenzes MT, Reed TE, Casper RF. Effects of cigarette smoking and age on the maturation of human oocytes. Hum Reprod. 1997;12(8):1736-1741.

Rosevear SK, Holt DW, Lee TD, et al. Smoking and decreased fertilisation rates in vitro. Lancet. 1992;340(8829):1195-1196.

Ge W, Li L, Dyce PW, et al. Establishment and depletion of the ovarian reserve: physiology and impact of environmental chemicals. Cell Mol Life Sci. 2019;76(9):1729-1746.

Burger HG. Androgen production in women. Fertil Steril. 2002;77 Suppl 4:S3-5.

Conforti A, Carbone L, Di Girolamo R, et al. Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2025;123(3):457-476.

Norman RJ, Alvino H, Hull LM, et al. Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reprod Biomed Online. 2019;38(6):908-915.

Choe SA, Kim MJ, Lee HJ, et al. Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled study. Arch Gynecol Obstet. 2018;297(3):791-796.

Lee YX, Shen MS, Tzeng CR. Low Dose Growth Hormone Adjuvant Treatment With Ultra-Long Ovarian Stimulation Protocol in Poor Responders Showed Non-inferior Pregnancy Outcome Compared With Normal Responders. Front Endocrinol (Lausanne). 2019;10:892.

Xu Y, Nisenblat V, Lu C, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reprod Biol Endocrinol. 2018;16(1):29.

Shang Y, Song N, He R, et al. Antioxidants and Fertility in Women with Ovarian Aging: A Systematic Review and Meta-Analysis. Adv Nutr. 2024;15(8):100273.

Artini PG, Tatone C, Sperduti S, et al. Cumulus cells surrounding oocytes with high developmental competence exhibit down-regulation of phosphoinositol 1,3 kinase/protein kinase B (PI3K/AKT) signalling genes involved in proliferation and survival. Hum Reprod. 2017;32(12):2474-2484.

Placidi M, Casoli G, Tatone C, et al. Myo-Inositol and Its Derivatives: Their Roles in the Challenges of Infertility. Biology (Basel). 2024;13(11).

Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162-1172.

Pantos K, Nitsos N, Kokkali G, et al. Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after autologous platelet-rich plasma treatment. Hum Reprod. 2016;31(Suppl 1):i301.

Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. J Clin Med. 2020;9(6).

Barrenetxea G, Celis R, Barrenetxea J, et al. Intraovarian platelet-rich plasma injection and IVF outcomes in patients with poor ovarian response: a double-blind randomized controlled trial. Hum Reprod. 2024;39(4):760-769.

Herraiz S, Romeu M, Buigues A, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril. 2018;110(3):496-505 e491.

Romanski PA, Bortoletto P, Rosenwaks Z, et al. Delay in IVF treatment up to 180 days does not affect pregnancy outcomes in women with diminished ovarian reserve. Hum Reprod. 2020;35(7):1630-1636.

Harris BS, Jukic AM, Truong T, et al. Markers of ovarian reserve as predictors of future fertility. Fertil Steril. 2023;119(1):99-106.

Polyzos NP, Popovic-Todorovic B. SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same. Hum Reprod. 2020;35(9):1964-1971.

Esteves SC, Carvalho JF, Martinhago CD, et al. Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model. Panminerva Med. 2019;61(1):3-10.

Polyzos NP, Blockeel C, Verpoest W, et al. Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria. Hum Reprod. 2012;27(12):3481-3486.

Kedem A, Tsur A, Haas J, et al. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation? Fertil Steril. 2014;101(6):1624-1628.

Garcia-Velasco JA, Bermejo A, Ruiz F, et al. Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertil Steril. 2011;96(3):590-593.

Hauzman EE, Zapata A, Bermejo A, et al. Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial. Reprod Biol Endocrinol. 2013;11:96.

Tsampras N, Gould D, Fitzgerald CT. Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients. Hum Fertil (Camb). 2017;20(4):248-253.

Cerrillo M, Cecchino GN, Toribio M, et al. A randomized, non-inferiority trial on the DuoStim strategy in PGT-A cycles. Reprod Biomed Online. 2023;46(3):536-542.

Vaiarelli A, Cimadomo D, Trabucco E, et al. Double Stimulation in the Same Ovarian Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved From Poor Prognosis Patients: A Multicenter Experience and SWOT Analysis. Front Endocrinol (Lausanne). 2018;9:317.

Ashrafi M, Arabipoor A, Yahyaei A, et al. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial. Reprod Biol Endocrinol. 2018;16(1):124.

Davar R, Neghab N, Naghshineh E. Pregnancy outcome in delayed start antagonist versus microdose flare GnRH agonist protocol in poor responders undergoing IVF/ICSI: An RCT. Int J Reprod Biomed. 2018;16(4):255-260.

Esfidani T, Moini A, Arabipoor A, et al. Early administration of gonadotropin-releasing hormone antagonist versus flexible antagonist ovarian stimulation protocol in poor responders: a randomized clinical trial. Middle East Fertility Society Journal. 2021;26(1):35.

Benadiva CA, Davis O, Kligman I, et al. Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients. J Assist Reprod Genet. 1995;12(1):8-12.

Casarini L, Santi D, Brigante G, et al. Two Hormones for One Receptor: Evolution, Biochemistry, Actions, and Pathophysiology of LH and hCG. Endocr Rev. 2018;39(5):549-592.

Devroey P, Pellicer A, Nyboe Andersen A, et al. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97(3):561-571.

Fauser BC, Alper MM, Ledger W, et al. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2011;22 Suppl 1:S23-31.

Drakopoulos P, Vuong TNL, Ho NAV, et al. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Hum Reprod. 2017;32(11):2225-2233.

Fusi FM, Zanga L, Arnoldi M, et al. Corifollitropin alfa for poor responders patients, a prospective randomized study. Reprod Biol Endocrinol. 2020;18(1):67.

Berkkanoglu M, Ozgur K. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil Steril. 2010;94(2):662-665.

Weil S, Vendola K, Zhou J, et al. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab. 1999;84(8):2951-2956.

Humaidan P, Chin W, Rogoff D, et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017;32(7):1537-1538.

Tosun SA, Ozkaya E, Aru B, et al. Does LH supplementation in poor responders affect granulosa cells apoptosis rate in ART? A prospective randomised controlled trial. J Obstet Gynaecol. 2022;42(1):133-138.

Dosouto C, Haahr T, Humaidan P. Advances in ovulation trigger strategies. Panminerva Med. 2019;61(1):42-51.

Keskin M, Ecemis T, Atik A, et al. Cycle outcomes of dual trigger (GnRH agonist+hCG) versus human chorionic gonadotropin trigger alone in POSEDION group 3-4 poor-responders and normo-responders: A prospective randomized study. J Gynecol Obstet Hum Reprod. 2023;52(8):102633.

Zagadailov P, Hsu A, Seifer DB, et al. Differences in utilization of Intracytoplasmic sperm injection (ICSI) within human services (HHS) regions and metropolitan megaregions in the U.S. Reprod Biol Endocrinol. 2017;15(1):45.

Check JH, Chase DS, Horwath D, et al. Oocytes from women of advanced reproductive age do not appear to have an increased risk of zona pellucida hardening. Clin Exp Obstet Gynecol. 2012;39(4):440-441.

Zhu S, Jiang W, Liao X, et al. Effect of diminished ovarian reserve on the outcome of fresh embryo transfer in IVF/ICSI cycles among young women: A retrospective cohort study. BMC Womens Health. 2024;24(1):230.

Hu YL, Wang Y, Geng LH, et al. Effects of sequential cleavage and blastocyst embryo transfer on pregnancy outcomes in patients with poor ovarian response. J Reprod Immunol. 2023;155:103780.

Wang SF, Seifer DB. Age-related increase in live-birth rates of first frozen thaw embryo versus first fresh transfer in initial assisted reproductive technology cycles without PGT. Reprod Biol Endocrinol. 2024;22(1):42.

Carnesi E, Castellano S, Albani E, et al. Diminished ovarian reserve is associated to euploidy rate: a single center study. Front Endocrinol (Lausanne). 2024;15:1535776.

Jaswa EG, McCulloch CE, Simbulan R, et al. Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. Fertil Steril. 2021;115(4):966-973.

Morin SJ, Patounakis G, Juneau CR, et al. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance. Hum Reprod. 2018;33(8):1489-1498.

Stovezky YR, Romanski PA, Bortoletto P, et al. Antimullerian hormone is not associated with embryo ploidy in patients with and without infertility undergoing in vitro fertilization with preimplantation genetic testing. Fertil Steril. 2023;119(3):444-453.

Transfer EGGotNoEt, Alteri A, Arroyo G, et al. ESHRE guideline: number of embryos to transfer during IVF/ICSIdagger. Hum Reprod. 2024;39(4):647-657.

Practice Committee of the American Society for Reproductive M, the Practice Committee for the Society for Assisted Reproductive Technologies. Electronic address Aao. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril. 2021;116(3):651-654.

Wang MJ, Lin MH, Yang JH, et al. Low antimullerian hormone (<1.2 ng/ml) does not impact oocyte quality and IVF/ICSI outcomes in women =40 years old. Taiwan J Obstet Gynecol. 2025;64(2):248-252.

Li NJ, Yao QY, Yuan XQ, et al. Anti-mullerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis. Arch Gynecol Obstet. 2023;308(1):43-61.